Rep. April McClain Delaney Purchases Shares of Laboratory Co. of America Holdings (NYSE:LH)

Representative April McClain Delaney (D-Maryland) recently bought shares of Laboratory Co. of America Holdings (NYSE:LH). In a filing disclosed on March 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Laboratory Co. of America stock on February 27th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Revvity (NYSE:RVTY) on 2/28/2025.
• Purchased $1,001 – $15,000 in shares of Laboratory Co. of America (NYSE:LH) on 2/28/2025.
• Purchased $15,001 – $50,000 in shares of Corpay (NYSE:CPAY) on 2/28/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/28/2025.
• Purchased $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/27/2025.
• Purchased $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/27/2025.
• Sold $15,001 – $50,000 in shares of Teledyne Technologies (NYSE:TDY) on 2/22/2025.
• Purchased $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of Tempur Sealy International (NYSE:TPX) on 2/22/2025.
• Sold $1,001 – $15,000 in shares of CACI International (NYSE:CACI) on 2/22/2025.

Laboratory Co. of America Price Performance

Shares of NYSE:LH opened at $233.97 on Friday. The company’s fifty day moving average is $245.16 and its two-hundred day moving average is $234.28. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $258.59. The company has a market cap of $19.58 billion, a P/E ratio of 26.53, a price-to-earnings-growth ratio of 1.71 and a beta of 1.12.

Laboratory Co. of America (NYSE:LH) last announced its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. Equities analysts expect that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.23%. The ex-dividend date was Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 32.65%.

Institutional Investors Weigh In On Laboratory Co. of America

A number of hedge funds have recently bought and sold shares of LH. Graney & King LLC bought a new stake in Laboratory Co. of America during the fourth quarter valued at about $26,000. SouthState Corp bought a new stake in Laboratory Co. of America during the third quarter valued at about $28,000. Fortitude Family Office LLC raised its position in shares of Laboratory Co. of America by 312.5% during the fourth quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares during the last quarter. Geneos Wealth Management Inc. raised its position in shares of Laboratory Co. of America by 309.8% during the fourth quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock valued at $39,000 after buying an additional 127 shares during the last quarter. Finally, Human Investing LLC acquired a new position in shares of Laboratory Co. of America during the fourth quarter valued at about $39,000. 95.94% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Adam H. Schechter sold 6,121 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $244.62, for a total transaction of $1,497,319.02. Following the completion of the transaction, the chief executive officer now owns 86,445 shares of the company’s stock, valued at approximately $21,146,175.90. This represents a 6.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kerrii B. Anderson sold 500 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $255.63, for a total transaction of $127,815.00. Following the transaction, the director now directly owns 13,166 shares of the company’s stock, valued at $3,365,624.58. This represents a 3.66 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,500 shares of company stock valued at $3,577,572. Insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. UBS Group lowered their price target on shares of Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Barclays lowered their price target on shares of Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a report on Friday, February 7th. Jefferies Financial Group boosted their price target on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Citigroup upgraded shares of Laboratory Co. of America from a “neutral” rating to a “buy” rating and boosted their price target for the company from $250.00 to $300.00 in a report on Tuesday, March 4th. Finally, Morgan Stanley upped their price objective on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Laboratory Co. of America currently has an average rating of “Moderate Buy” and a consensus target price of $268.38.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.